Comparison of Efficacy and Safety Between Immunotherapy and Docetaxel Monotherapy in NSCLC Patients

Overview of attention for article published in Frontiers in oncology, August 2022

Altmetric Badge

Mentioned by

twitter: 2 X users

Readers on

mendeley: 3 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 13,914 followers.

RT @FrontOncology: New research: Comparison of Efficacy and Safety Between Immunotherapy and Docetaxel Monotherapy in NSCLC Patients: Objec…

11 Aug 2022

Reply Repost Favourite

New research: Comparison of Efficacy and Safety Between Immunotherapy and Docetaxel Monotherapy in NSCLC Patients: Objective Meta analysis was used to compare the efficacy and safety of immune checkpoint inhibitor and docetaxel in the… https://t.co/QHq2p9

11 Aug 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.